SEHK:2171Biotechs
Early Clinical Success of Allogeneic CAR-T Therapies Might Change The Case For Investing In CARsgen Therapeutics (SEHK:2171)
CARsgen Therapeutics announced recent clinical data highlighting initially favorable safety and encouraging efficacy from its allogeneic CAR-T therapies, CT0596 and CT1190B, in relapsed/refractory multiple myeloma and non-Hodgkin's lymphoma, with several patients achieving deep responses after extensive prior treatments.
The progress includes advancement into expanded clinical trial phases and signals plans to submit an Investigational New Drug application, reflecting ongoing momentum in...